GSK plc announced that Japan's Ministry of Health approved Nucala for treating adults with chronic rhinosinusitis with nasal polyps on August 28, 2024. The approval is based on clinical trials showing significant improvements in nasal obstruction symptoms and a new treatment alternative for approximately 200,000 patients in Japan who require surgery for this condition.